

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Botanix Pharmaceuticals Limited
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Vincent Ippolito
<b>Date of last notice</b>	17 January 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust
<b>Date of change</b>	8 October 2025
<b>No. of securities held prior to change</b>	<p><b>Vincent Peter Ippolito</b></p> <ul style="list-style-type: none"> <li>8,000,000 Fully Paid Ordinary Shares</li> <li>16,000,000 Performance Rights (expiring 2 December 2029)</li> </ul> <p><b>Vincent Peter Ippolito and Karen Ann Ippolito &lt;The Ippolito Trust&gt; - trustee and beneficiary of the trust</b></p> <ul style="list-style-type: none"> <li>7,001,644 Fully Paid Ordinary Shares</li> </ul>
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	8,000,000 Fully Paid Ordinary Shares
<b>Number disposed</b>	8,000,000 Fully Paid Ordinary Shares
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.14 per Fully Paid Ordinary Share

<b>No. of securities held after the change</b>	<b>Vincent Peter Ippolito</b> <ul style="list-style-type: none"> <li>16,000,000 Performance Rights (expiring 2 December 2029)</li> </ul> <b>Vincent Peter Ippolito and Karen Ann Ippolito &lt;The Ippolito Trust&gt; - trustee and beneficiary of the trust</b> <ul style="list-style-type: none"> <li>15,001,644 Fully Paid Ordinary Shares</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off-market transfer of 8,000,000 fully paid ordinary shares from a direct to indirect holding.

## Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

For personal use only